Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

CCR 20th Anniversary Commentary

CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies—Immuno-oncology Advances Clinical Cancer Research

Dominik Wolf and Anna Maria Wolf
Dominik Wolf
1Medical Clinic III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany.
2Laboratory of Tumor Immunology, Department of Medicine V, Medical University Innsbruck, Innsbruck, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dominik.wolf@ukb.uni-bonn.de anna_maria.wolf@ukb.uni-bonn.de
Anna Maria Wolf
1Medical Clinic III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany.
2Laboratory of Tumor Immunology, Department of Medicine V, Medical University Innsbruck, Innsbruck, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dominik.wolf@ukb.uni-bonn.de anna_maria.wolf@ukb.uni-bonn.de
DOI: 10.1158/1078-0432.CCR-14-2558 Published June 2015
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Immune escape is a hallmark of cancer development and metastasis. Regulatory T cells (Treg) are potent inhibitors of cancer immune surveillance but also prevent inflammation-driven tumorigenesis. The study by Wolf and colleagues, which was published in the February 2003 issue of Clinical Cancer Research, showed the expansion of Treg in solid cancer patients, providing a deeper understanding of cancer immune escape mechanisms that later set the stage for the development of scientific breakthroughs in cancer immunotherapy. Clin Cancer Res; 21(12); 2657–9. ©2015 AACR.

See related article by Wolf et al., Clin Cancer Res 2003;9(2) Feb 2003;606–12

  • Received February 5, 2015.
  • Accepted February 20, 2015.
  • ©2015 American Association for Cancer Research.

View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 21 (12)
June 2015
Volume 21, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies—Immuno-oncology Advances Clinical Cancer Research
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies—Immuno-oncology Advances Clinical Cancer Research
Dominik Wolf and Anna Maria Wolf
Clin Cancer Res June 15 2015 (21) (12) 2657-2659; DOI: 10.1158/1078-0432.CCR-14-2558

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies—Immuno-oncology Advances Clinical Cancer Research
Dominik Wolf and Anna Maria Wolf
Clin Cancer Res June 15 2015 (21) (12) 2657-2659; DOI: 10.1158/1078-0432.CCR-14-2558
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Cell Transfer Immunotherapy for Human Cancer
  • MAPK/ERK Inhibition in Melanoma: Kinase Inhibition Redux
  • ALK Fusion Clinicopathologic Features
Show more CCR 20th Anniversary Commentary
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement